ODM-201
|
|
|
- CAS-Nr.
- 1297538-32-9
- Englisch Name:
- ODM-201
- Synonyma:
- Darolutamide;BAY-1841788;0DM021;ODM 021;ODM-201;CS-1565;ODM-021;Darolutamid;Darrolumide;Darolutamide D4
- CBNumber:
- CB43052901
- Summenformel:
- C19H19ClN6O2
- Molgewicht:
- 398.85
- MOL-Datei:
- 1297538-32-9.mol
|
ODM-201 Eigenschaften
- Schmelzpunkt:
- 169 - 171°C
- Siedepunkt:
- 719.5±60.0 °C(Predicted)
- Dichte
- 1.41±0.1 g/cm3(Predicted)
- storage temp.
- -20°C Freezer, Under inert atmosphere
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 11.10±0.10(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
ODM-201 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
ODM-201 is a novel androgen receptor (AR) inhibit designed to inhibit the growth of prostate cancer cells through binding to the AR to inhibit the testosterone-induced AR nuclear translocation. It is particularly used in patients with progressive metastatic castration-resistant prostate cancer. It is effective in inhibiting the activity of some mutant ARs emerging during antiandrogen therapies, including the F876L mutation version which is resistant to enzalutamide and ARN-509 (the second-generation antiandrogens).Therefore, it has potential to overcome the resistance issue occurring upon AR-targeted therapies.
Verwenden
ODM-201 is a compound being used as a novel next-generation androgen receptor-directed therapy for prostate cancer.
Einzelnachweise
Moilanen, Anu Maarit, et al. "Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies." Sci Rep 5.2(2015):12007.
Fizazi, Karim, et al. "ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data." Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of 2013.
Fizazi, K, et al. "Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial." Lancet Oncology 5.9(2014):975-85.
ODM-201 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
ODM-201 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 214)Lieferanten
- ODM-201
- N-[(1S)-2-[3-(3-Chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
- N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
- Darolutamide (ODM-201)
- ODM-201(BAY-1841788)
- CS-1565
- ODM-201(Darolutamide)
- N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)-1-hydroxyethyl]-1H-pyrazole-3-carboxamide
- 0DM021
- BAY-1841788;ODM-021;0DM021;ODM 021
- ODM 021
- ODM-021
- DAROLUTAMIDE;BAY-1841788
- 1H-Pyrazole-3-carboxamide, N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-5-(1-hydroxyethyl)-
- Darolutamid
- Darolutamide D4
- N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-[(1RS)Chemicalbook-1-hydroxyethyl]-1H-pyrazole-3-carboxamide
- TIANFUCHEM--1297538-32-9---ODM-201
- BAY-1841788
- Darolutamide
- N-[(2S)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide
- N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-3-(1-hydroxyethyl)-1H-pyrazole-5-carboxamide
- Darolutamide, ODM-201,BAY-1841788
- Darrolumide
- Dantrolene Impurity 6
- 1297538-32-9
- C19H19ClN6O2
- API
